BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29618348)

  • 1. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.
    Wu YR; Shi XY; Ma CY; Zhang Y; Xu RX; Li JJ
    Cardiovasc Diabetol; 2019 Nov; 18(1):146. PubMed ID: 31706303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
    Yang X; Zhang J; Chen L; Wu Q; Yu C
    Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
    Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
    J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
    Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
    BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
    Dong B; Singh AB; Shende VR; Liu J
    Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
    Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
    Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor Through
    Hwang JT; Kim HJ; Choi HK; Park JH; Chung S; Chung MY
    J Med Food; 2020 Oct; 23(10):1102-1108. PubMed ID: 32835593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
    Dong B; Li H; Singh AB; Cao A; Liu J
    J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
    Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
    Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
    Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
    Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR).
    Ji J; Feng M; Niu X; Zhang X; Wang Y
    Bioengineered; 2021 Dec; 12(1):8057-8066. PubMed ID: 34666623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.